H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, develops and markets drugs for the treatment of psychiatric and neurological disorders. It undertakes research and development, production, marketing, and sale of pharmaceuticals worldwide. The company offers products for the treatment of CNS disorders such as depression and anxiety, schizophrenia, migraine, epilepsy, Alzheimer's and Parkinson's diseases, and other CNS disorders. Lundbeck's research and development efforts are focused on developing new and improved treatments. The company also provides evidence-based medical education and training for healthcare professionals.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lundbeck R&D arm focuses on developing transformative medicines for neurological disorders. The company's R&D efforts are driven by a commitment to understanding the underlying mechanisms of brain diseases, utilizing state-of-the-art research centers in Denmark and California, and collaborating with global partners. Lundbeck's pipeline aims to deliver novel therapies that redefine the standard of care, with a focus on neuro-specialty and neuro-rare conditions. The company is also leveraging AI and digital tools to enhance its R&D processes and accelerate clinical trials. The R&D units of Lundbeck are located in Denmark and California, US. These units are responsible for managing the company's R&D activities, focusing on the discovery and development of new pharmaceuticals targeting brain diseases. The units integrate advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs. The company has a robust pipeline with multiple products in various stages of development, including late-stage assets and early-phase projects. Lundbeck has formed major technology alliances, such as partnerships with 23andMe, Inc., The Milken Institute, and Iambic Therapeutics, to enhance its research capabilities and explore innovative treatment options. In FY2025, Lundbeck spent DKK4,957 million on its R&D activities, which as a percentage of revenue, stood at 20.1% and grew 27.5%. It has research centers in the US and Denmark.